Takeda bets $100M upfront on AC Immune's anti-amyloid Alzheimer's vaccine
VaccineImmunotherapyLicense out/in
AC Immune has lined up its third pharma partner in Alzheimer’s disease, and the pact comes with a hefty biobucks package.
Takeda will pay AC Immune $100 million upfront to snag the exclusive option to license the Swiss biotech’s anti-amyloid vaccine, which is in Phase 1b/2 testing in the US and Europe. If the drugmaker opts to further develop the immunotherapy, dubbed ACI-24.060, it could dish out up to another $2.1 billion in option fees and milestones, the companies said Monday morning.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.